Showing results (61-70 of 77) with videos related to
Sort By:
Pageof 8
Pharmacoepidemiology and Drug Safety|December 11, 2024
Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease StatusVincent Lo Re, Craig W Newcomb, Dean M Carbonari, et al.JAMA Internal Medicine|June 24, 2024
Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World DataJessie Torgersen, Alyssa K Mezochow, Craig W Newcomb, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 1, 2015
Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic ModelVincent Lo Re, Kevin Haynes, Kimberly A Forde, et al.Journal of the National Cancer Institute|November 6, 2019
HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis StatusJessie Torgersen, Michael J Kallan, Dena M Carbonari, et al.Plos One|July 23, 2025
Magnetic resonance evaluation of three-dimensional liver fat fraction by hepatitis C status and associations with inflammatory cytokinesJessie Torgersen, Craig W Newcomb, Dean M Carbonari, et al.BMJ Open|March 19, 2026
Postmarketing safety surveillance for GSK's AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in the USA: protocol for a non-interventional postauthorisation safety studySruthi Adimadhyam, Dominique Luyts, Driss Oraichi, et al.Pharmacoepidemiology and Drug Safety|April 22, 2021
Validity of ICD-10-CM diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapiesVincent Lo Re, Dena M Carbonari, Jerry Jacob, et al.BMJ Open Diabetes Research & Care|September 8, 2017
Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomesVincent Lo Re, Dena M Carbonari, M Elle Saine, et al.Open Forum Infectious Diseases|May 5, 2017
Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis StatusCharitha Gowda, Craig W Newcomb, Qing Liu, et al.Pharmacoepidemiology and Drug Safety|July 6, 2012
Safety of saxagliptin: rationale for and design of a series of postmarketing observational studiesVincent Lo Re, Kevin Haynes, Eileen E Ming, et al.Pageof 8